Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer
Purpose of the study. Assessment of clinical safety and effectiveness of radium‑223 in patients with bone metastases from castration-resistant prostate cancer.Patients and methods. The study involved materials on 15 patients with bone metastases from castration-resistant prostate cancer aged 58–81 y...
Saved in:
| Main Authors: | O. I. Kit, N. A. Maksimova, M. A. Gusareva, A. N. Shevchenko, M. S. Zinkovich, M. G. Ilchenko, K. P. Boyko, A. V. Faenson, S. N. Dimitriadi, L. Ya. Rozenko |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ANO "Perspective of oncology"
2024-12-01
|
| Series: | Южно-Российский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.cancersp.com/jour/article/view/272 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01) -
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Colleen Mackenzie, et al.
Published: (2024-10-01) -
Multicenter, international, retrospective study of prognostic factors for Ra223
by: Takuya Oishi, et al.
Published: (2025-03-01) -
Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
by: John Buscombe, et al.
Published: (2021-04-01) -
Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges
by: Amit Bhoil, et al.
Published: (2022-12-01)